A show discussing the important academic and other research in the field of Psychedelics. We discuss how psychedelics relate to human potential and healing.
psychedelics, integration, solidarity, consciousness, relatively, efforts, states, amazing guests, leading, besides, example, great topics, great resource, met, field, educational, chance, fascinating.
Listeners of Psychedelics Today that love the show mention: kyle and joe, joe and kyle,The Psychedelics Today podcast is an excellent resource for anyone interested in the psychedelic space. It provides valuable content and keeps listeners up to date on the latest happenings in the field. The podcast features a variety of voices, offering diverse perspectives without any hype. It encourages listeners to think, learn, and explore further.
One of the best aspects of this podcast is its coverage of the legitimization of psychedelic experiences in therapy, spirituality, and recreation. The hosts bring many voices to the table and strive to mainstream the conversation surrounding psychedelics. This approach is refreshing and serves humanity by promoting education and awareness.
Another standout aspect of the podcast is that it acknowledges differing opinions within the industry. It addresses scientific viewpoints that may look down on or show contempt for those who choose not to go to a clinic or work with a psychiatrist for their psychedelic experience. By including multiple perspectives, the podcast allows listeners to consider both sides of the discussion.
A possible drawback of this podcast is that it may not delve into scientific topics deeply enough for some scientists or experts in the field. While it covers the science behind psychedelics, it does so in a way that non-scientists can follow. This approach may be appreciated by beginners or those seeking a general understanding but may leave some wanting more detailed scientific discussions.
In conclusion, The Psychedelics Today podcast is highly recommended for anyone new to the psychedelic movement or seeking up-to-date information on psychedelics. It offers informative interviews with experts and covers a wide range of topics without overwhelming listeners with technical jargon. With each episode, it continues to improve and deliver valuable content. Whether you're curious about psychedelics, interested in therapy options, or simply looking to expand your knowledge, this podcast is worth listening to.
Interviewers: Joe Moore & Anne Philippi Guests: TK Wonder & Cipriana Quann (The Quann Sisters) Recorded: June 18 during MAPS PS 2025 Content note: This episode discusses childhood sexual, physical, and emotional abuse, suicidal ideation, disordered eating, and recovery. Identical twins, writers, and culture-shapers TK Wonder and Cipriana Quann join Joe and Anne for a frank, generous conversation about identity, resilience, and the long arc of healing. Cipriana recounts launching Urban Bush Babes in 2011 to center women of color in beauty and fashion—work that led to a Vogue “day-in-the-life” feature and collaborations with couture houses. TK shares the parallel path of her music career (opening for artists from Sting and Nas to Erykah Badu and Queens of the Stone Age) and the sisters' ongoing writing, public speaking, and mental-health advocacy. They reflect on the fashion industry's policing of natural hair, how those daily microaggressions erode self-worth, and why legal protections like the CROWN Act matter. The heart of the episode is their survival story: a decade of abuse by their father, endured separately yet witnessed together. Seeing one another live through it—“a physical manifestation of survival,” as they put it—kept them alive. As adults, daily check-ins remain their core practice. Psychedelics entered their lives years later. With careful set and setting, education, and professional support, psychedelic sessions—especially ibogaine—helped surface grief, release shame, and reframe entrenched coping strategies. Cipriana's first extended session unlocked tears she'd been forced to suppress as a child; TK describes a transformative ibogaine experience that catalyzed a decisive shift away from refined sugar and ultra-processed foods toward sustained movement, earlier mornings, and mindful nourishment. Both emphasize that psychedelics are not “magic pills” in isolation: integration, therapy, community, and lifestyle design make insights durable. The conversation also tackles safety and access. The sisters stress working with experienced facilitators and medical oversight, naming that these modalities aren't for everyone. They call for more affordability and BIPOC representation in a field that can still feel exclusionary, while holding a wide tent vision—everyone deserves the chance to heal. They note how narratives are changing (from early-2000s panic to mainstream book-club conversations), and how stories alongside science move culture and policy. Highlights Fashion, hair politics, and the CROWN Act's importance. Sisterhood as lifeline; daily check-ins as grown-up therapy. First sessions: somatic release, grief, and reframing shame. Ibogaine's role in behavior change; why integration is the bridge. Safety, access, and representation: making healing containers truly welcoming. If you're exploring this work: educate deeply, choose qualified support, prioritize integration, and remember—your past is a chapter, not your whole story.
In this candid, practice-focused conversation, Joe is joined by Norwegian psychologist and researcher Ivar Goksøyr to explore how therapists' own healing journeys can measurably improve client outcomes—and why MDMA-assisted experiences, used thoughtfully, may be a uniquely powerful catalyst for professional development. Ivar shares lessons from Norway's psychedelic research team (PTSD and the world's first MDMA-for-depression trial), his clinic Psykologvirke in Oslo, and his online course, “The Wounded Healer,” which uses authentic footage from his FDA-approved MAPS volunteer MDMA sessions to illuminate real clinical processes, countertransference, and the “inner healing intelligence” as a working metaphor rather than dogma. The discussion ranges from implementation realities (laws, ethics, and conservative regulatory cultures) to the pragmatic: how an MDMA experience helped Ivar resolve chronic anxiety reactions in the therapy chair, reduced burn-out, increased receptivity, and improved attunement—changes he believes many clinicians can cultivate when personal growth is prioritized alongside methods training. He outlines a developing collaboration with the University of Oslo on Empathogen-Assisted Therapies Development—not to “dose for certification,” but to support therapists' self-awareness and resilience in legally sanctioned research contexts. They also compare compounds: why MDMA may be easier to integrate into mainstream psychiatry than classic tryptamines (fewer projective processes, more biographical focus, smoother affect regulation), while acknowledging the immense promise—and higher demands—of psilocybin and other psychedelics. Throughout, they emphasize humility, guardrails, and the need to keep learning as the field scales (with frank reflections on ketamine's mixed rollout and avoiding idealization/devaluation cycles). Highlights Why therapist factors often outweigh modality—and how personal work translates into better outcomes. Using real session video (with Ivar as participant) to normalize vulnerability, illuminate process, and train pattern recognition. Regulatory and ethical nuances of self-experience in training; building consensus before policy change. Inner healing intelligence as a clinical metaphor aligned with Rogers, Rank, and psychodynamic concepts (unconscious therapeutic alliance). MDMA vs. classic psychedelics for implementation; sequencing with ketamine in public systems. Global classroom: 270+ clinicians from every continent; course structure centered on reflection, discussion, and live analysis.
Joe and Kyle debrief a hometown Dreamshadow Transpersonal Breathwork weekend in Breckenridge, then sketch the next chapter for Psychedelics Today: a community-centric model (Navigators) that bundles education, live streams, book and film clubs, and small-group access. They kick around the big “creativity + psychedelics” question, contrast subjective “I feel creative” with objective task performance, and highlight new research—from DMT's potential in stroke recovery to breathwork's measurable effects. They wrap with quick hits on MAPS leadership, state policy moves, and what's coming up at PT this fall. Highlights & takeaways Breathwork > substance? A reminder that profound states are accessible without drugs; benefits of facilitating at home (rested facilitators = safer, better containers). What is “shamanism,” really? A functional frame: non-ordinary states, interaction with the unseen, and service (healing/divination). Community > one-off courses: PT is shifting toward a monthly membership model to keep prices accessible, deepen relationships, and sustain more free content. Creativity debate: Double-blind study (DMT + harmine vs harmine vs placebo) suggests impaired convergent thinking despite increased felt creativity; how to define and measure “creativity” fairly, and other research outcomes might tell a different story. Whitehead & novelty: A quick tour through Alfred North Whitehead's notion of “creativity” as the principle of novelty—useful language for mapping psychedelic insight to real-world change. Neuro + clinical frontiers: DMT for stroke (animal models): BBB stabilization and reduced neuroinflammation signal a promising adjunct to current care. Cluster headaches: Emerging reports on short-acting DMT for rapidly aborting cluster cycles; more data coming soon. Breathwork science: New imaging work associates music-supported hyperventilatory breathwork with blissful affect and shifts in blood flow. News & culture mentioned MAPS leadership: Betty Aldworth & Ismail (Izzy) Ali named permanent Co-Executive Directors. Policy snapshots: Colorado Natural Medicine Board recommending ibogaine (with Nagoya-compliance requirement); Alaska signature gathering; Massachusetts activity. Media & scene: Hamilton's recent appearances; contamination concerns in some “psilocybin” products; “psychedelics tick far more neurons than expected” paper; mixed findings for postpartum depression.
Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families. Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u
Joe and Kyle celebrate Vital Cohort 4 and reflect on why Vital is more than a 12-month psychedelic-informed training—it's a living community (alumni webinars, discussion groups, cross-cohort meetups). Many grads aren't rushing to facilitate; they're choosing integration, harm reduction, education, and local community building. Next cohort dates are TBD —applications and email sign-ups are open. Breathwork in Breckenridge (this weekend) Dreamshadow Transpersonal Breathwork returns Fri–Sun. The last workshop reinforced how powerful the format is for bonding, somatic processing, and ongoing peer support. Music & tech: fail-safe playbook Keep redundant sources: primary laptop with WAV/FLAC (VLC/Mixxx), secondary device/phone, and a small Bluetooth speaker as last resort. Redundant mixers/interfaces, tested cables, simple signal flow. Pre-flight the exact rig; monitor for digital artifacts/grounding noise. Use offline playlists + Do Not Disturb (actually test it). Why community matters now With AI accelerating “dead-internet” dynamics, trusted human networks—book clubs, film clubs, local meetups—are essential. Skills for the moment: digital security hygiene and discernment (evaluating claims, sources, and inner signals). News & trends Alaska: statewide psilocybin initiative begins signature gathering. New Mexico: momentum toward group psilocybin care (cost-cutting models; ~2-year horizon). TBI & psychedelics: expanding research interest (ibogaine/5-MeO imaging work; anti-inflammatory angles). Colorado & iboga: advisory board backs therapeutic use and encourages Nagoya Protocol reciprocity; federal import/legal nuances remain. Harm-reduction notes Beware gas-station/head-shop “psychedelic” edibles labeled as “proprietary blends.” Ask for COAs and clear ingredients; understand test-kit limits (chocolates are tricky). For injections (even “legal” clinics), ask about sterile technique, water, dosing, and sourcing. Get involved Navigators: join our membership for exclusive livestreams, book/film clubs, courses, and meetups. Vital: apply or join the interest list—dates announced soon.
Joe Moore sits down with Greg Shanken (Colorado Psychedelic Society, Collaborence Psychedelic Business Association; founder, Higher Frequency Network) for a wide-ranging conversation about building community infrastructure, navigating censorship, and creating accessible, ethical pathways into psychedelic healing. Greg shares his personal arc from lifelong depression to ayahuasca, ketamine, and Bufo; why he launched a vetted affiliate/partner network for our space; and how Oregon–Colorado collaboration can widen access while honoring reciprocity and conservation. Key themes Collaborence: a two-day CO/OR event (online + in-person) connecting facilitators, professionals, and the public with pay-what-you-can access options. Access & affordability: how to widen entry points (microdosing, breathwork, scholarships/funds) within and beyond regulated service/healing centers. Censorship & platform risk: why repeated Meta account shutdowns pushed Greg to build community-based distribution outside big ad networks. Personal journey: depression, SSRIs/SNRIs/ADHD meds → ayahuasca (two-night initiation), IM ketamine, and later Bufo/5-MeO-DMT. Ethics & ecology: “blood toad,” conservation, and the case for synthetic 5-MeO-DMT over toad-sourced material; parallels with peyote/mescaline carve-outs. Leadership & culture: bringing heart-centered leadership, breathwork, and microdosing into companies; moving from transactional to mutual-aid ecosystems. Regulated vs. underground: costs, insurance realities, sliding-scale models, and the role each plays in a healthy landscape.
In this episode of Psychedelics Today, Joe Moore sits down with Dr. Cat Meyer, licensed psychotherapist, sex therapist, and host of Sex, Love, Psychedelics. Together, they explore the deep intersections of sexuality, trauma healing, psychedelics, and the role of play in human connection. Dr. Meyer shares her journey from growing up in rural Missouri and navigating early trauma to becoming a leading voice in sex therapy and psychedelic integration. She opens up about her personal healing path, her work with ketamine-assisted therapy, and how tantra, BDSM, and art have shaped her approach to erotic wellness. Topics Covered Defining the Erotic: Beyond sex, eroticism as vibrancy, life force, and connection to the senses. Personal Story: Dr. Meyer's early struggles, academic path in marriage and family therapy, and her discovery of tantra and BDSM as transformative practices. Psychedelics and Healing: Her first experiences with MDMA-assisted therapy, ketamine retreats for women, and how these tools can reconnect people with pleasure and embodiment. The Power of Play: Why play is essential for healing, relationships, and cultural transformation—ranging from improv and art to Burning Man experiments. Navigating Power Dynamics: How erotic transference, facilitation, and unconscious needs can shape therapy, sex, and psychedelic work—and why self-awareness is crucial. Feral Mysticism: Rewilding the body, reclaiming personal authority, and embracing vibrancy outside of cultural repression. Pleasure and Illness: How Dr. Meyer works with clients facing chronic pain, fatigue, or illness to maintain erotic connection through presence and small practices. Key Quotes “Eroticism is the connection to vibrancy, to life—it's how we engage with the world through pleasure.” “Feeling is power. A discerning human who can feel is a powerful human.” “Psychedelics help us come back into right relationship with our body and with pleasure.” “Play gives us the freedom to experiment, to try, to be vulnerable, and to learn without attaching our worth to the outcome.”
Joe Moore interviews Dee Dee Goldpaugh, LCSW about their new book Embrace Pleasure: How Psychedelics Can Heal Our Sexuality. The discussion covers the book's reception, critiques of over-medicalization, personal healing experiences, definitions of erotic energy and pleasure, historical repression of substances, and contemporary ethical concerns. Key topics Conversion therapy: historical use of psychedelics in conversion practices, risks today, and need for professional consensus to ban psychedelic-assisted conversion therapy. Motivation: reaction to dominance of the clinical/medical model in psychedelics. Author background: clinical social worker, ketamine-assisted therapy provider, sexual abuse survivor, early psychedelic integration work. Personal healing: ayahuasca and San Pedro (Wachuma) experiences leading to embodied healing and pleasure. Concepts defined: erotic energy as life force; distinction between healing pleasure and leisure. Political framing: pleasure as anti-capitalist resistance; sustaining community and activism. Links https://www.deedeegoldpaugh.com Embrace Pleasure: How Psychedelics Can Heal Our Sexuality
From the Rave Scene to Psychedelic Therapy In this episode, Kyle Buller speaks with Matt Xavier, DJ, therapist, and author. The conversation took place live at Psychedelic Science. Matt recalls his early years in the rave culture of 1990s New York. He ran record labels, hosted psychedelic trance events, and lived through the intensity of that scene. Why Music Is Medicine Matt believes music should be treated as medicine. He explains how playlists can align with the stages of a psychedelic journey—onset, climb, peak, and descent. He encourages people to listen with intention and to categorize tracks by emotion, energy, and therapeutic impact. Psychedelic Soundtracking Instead of relying only on fixed playlists, Matt performs live mixing during sessions. This method keeps him fully engaged and responsive. He calls the approach “psychedelic soundtracking.” In his view, the guide becomes a tuning fork, adjusting the soundscape to match the client's process. Key Themes in the Conversation The evolution from rave DJ to therapist and author How music amplifies psychedelics, and why it matters Matching music with each stage of a journey Differences between psilocybin, MDMA, and ketamine work The value of silence, long-form tracks, and harmonic mixing Why buying music supports artists and protects creativity from AI Practical tips for building playlists and rediscovering a love of listening Supporting Artists and Building Community Matt highlights the artists who inspire his work, from ambient pioneers to contemporary sound designers. He urges practitioners to support independent musicians by purchasing their music. In his words, keeping human creativity alive is essential for meaningful psychedelic work. Writing, Mixing, and the Future Matt also discusses his new book and the curated four-hour DJ protocol mix he designed for therapy sessions. He explains how this project grew into a collaborative effort and why writing became a spiritual journey for him. Looking ahead, he hopes to create a training program for others interested in weaving music into psychedelic practice.
In this episode, Joe Moore sits down with Dr. Case Newsom, an emergency room physician in Denver and Medical Director for both Zendo Project and Stadium Medical. They explore how psychedelic harm reduction is merging with event medicine at concerts, festivals, and large-scale gatherings. Dr. Newsom shares his path from osteopathic medical training to bridging emergency medicine with psychedelic peer support. He explains how the Zendo Project has expanded beyond Burning Man, and why collaboration with medical teams matters. The discussion highlights new triage protocols, cultural shifts in Colorado, and the legal challenges that still stand in the way of safer events. Topics Covered The role of the Zendo Project: Peer support, harm reduction, and creating grounded spaces in chaotic environments. Stadium Medical's model: Covering Denver's biggest venues and connecting emergency care with psychedelic peer support. Developing medical triage protocols: A simple system that reduces unnecessary ER transports while ensuring sitter and guest safety. Colorado as a hub: Why Denver and Red Rocks are central to psychedelic culture and harm reduction innovation. Legal and regulatory challenges: The impact of the RAVE Act and limits on drug checking services. Research and data collection: Building stronger studies to show venues and first responders the value of harm reduction. Future concerns: Ibogaine's cardiotoxic risks, the rise of AI-designed drugs, and why medical involvement is urgent. Ketamine in the ER: How ketamine provides pain relief and can create meaningful patient experiences when used with care.
In this episode, Joe Moore is joined by Kat Murti, Executive Director of Students for Sensible Drug Policy (SSDP), the largest youth-led network working to end the war on drugs. SSDP organizes at the campus, local, state, federal, and international levels, with more than 100 chapters across the U.S. and sister organizations worldwide. Kat shares her personal journey into drug policy reform, from witnessing DEA raids on AIDS patients in the 1990s to fighting for civil liberties as a student at UC Berkeley. She explains how SSDP empowers young people to challenge outdated laws and promote policies rooted in compassion, scientific evidence, and human rights. Topics Discussed The War on Drugs as a War on Us: Kat's early realizations about the drug war's racism, injustice, and destruction of civil liberties. Her Path to SSDP: From working on California's Prop 19 cannabis campaign to serving on SSDP's board and eventually becoming Executive Director. Meta Censorship Campaign: Why Meta's restrictions on drug education and harm reduction content harm communities, and how SSDP is organizing public pressure to protect freedom of information online. Forced Institutionalization & Executive Orders: Kat critiques recent federal moves to expand forced treatment, cuts to naloxone training programs, and the misguided use of tariffs as “solutions” to the overdose crisis. The Fight Against DEA Scheduling of DOI & DOC: Why these research chemicals are vital to neuroscience and medicine, how SSDP challenged the DEA in court, and what's at stake for future research. Illogical Drug Policy & Careerism: How prohibition persists due to political incentives, propaganda, and entrenched bureaucratic interests. Building a Better Future: Realigning incentive structures, embracing harm reduction, and supporting community-based solutions to drug use. Key Takeaways The war on drugs is deeply racist, anti-science, and erodes civil liberties. Meta's censorship of harm reduction information actively endangers lives. Forced treatment doesn't work—addressing social conditions and providing safe housing does. DOI and DOC, rarely if ever used recreationally, are critical to medical research, and scheduling them would halt decades of progress. Real reform means both ending prohibition and creating environments where people feel supported, connected, and empowered. Links & Resources Students for Sensible Drug Policy (SSDP): ssdp.org Kat Murti on Twitter/X: @KatMurti Kat Murti on Instagram: @KittyRevolution SSDP Petition against Meta Censorship: ssdp.org
In this episode, Joe Moore is joined by Mareesa Stertz and Tania Abdul, the visionaries behind Sphinx Gate, one of Burning Man 2025's most ambitious and mythic art installations. Inspired by The NeverEnding Story, Sphinx Gate features two towering 34-foot sphinxes and a fully immersive, transformative art experience designed to help participants gain a deeper understanding of themselves. The trio explores how art and play can catalyze personal and collective transformation—without the need for psychedelics—by helping people reframe inner challenges as quests for growth. They discuss the project's mythic inspiration, how it has evolved into a “transmersive” self-discovery journey, and how community co-creation has made this dream real. With rituals, interactive stations, laser-eyed sphinxes, and an oracle offering personalized missions, Sphinx Gate blends storytelling, inner work, and spectacle. They also touch on the deeper intention: shifting culture by normalizing integration, peer support, and emotional exploration—through joy. From honoring Indigenous land stewards to designing future traveling versions and permanent “Museums of Self-Exploration,” this project is just the beginning. Topics Covered: What Sphinx Gate is and how it works The archetypal and cultural roots of sphinxes How The NeverEnding Story inspired the vision Designing integration spaces without psychedelics Co-creation, community magic, and scaling big dreams The emotional and mystical potential of participatory art Fantasia Fridays, Black Rock Philharmonic, and more playa programming Vision for life beyond Burning Man Support Sphinx Gate: Help bring this mythic experience to life and fund its future by donating at TheSphinxGate.com Follow: IG: @thesphinxgate www.thesphinxgate.com
In this episode of Psychedelics Today, Joe Moore sits down with Chad Charles — educator, mentor, and practitioner specializing in 5-MeO-DMT therapy. Chad shares his decade-long journey working with 5-MeO-DMT, emphasizing the importance of: Practitioner training and mentorship Personalized, therapeutic alliances The nuanced understanding of dissociative states Ethics in standardized clinical dosing A trauma-informed approach to psychedelic care He also introduces his upcoming research project, analyzing 500+ one-on-one sessions to illuminate best practices and ethical frameworks in the 5-MeO-DMT space. This is a must-listen for anyone passionate about harm reduction, responsible facilitation, and the future of psychedelic therapy.
In this episode of Psychedelics Today, Joe Moore sits down with Alan Davis, Associate Professor at Ohio State University, to explore the evolving landscape of Ibogaine research and its therapeutic potential. Alan offers a deep dive into the Iboga Patient Survey, a groundbreaking initiative collecting real-world data on the safety and efficacy of Ibogaine—particularly for those struggling with substance use disorders and mental health challenges. The conversation sheds light on the need for rigorous, community-informed research that could pave the way toward FDA approval and increased access for patients, including veterans dealing with trauma. They also discuss the complexities of clinical trials, the tension between state and federal regulations, and the growing influence of corporate interests in psychedelic research. Alan emphasizes the importance of ethical transparency, community collaboration, and maintaining scientific integrity as the field grows. If you're curious about the intersection of psychedelic medicine, clinical research, and patient safety, this is a must-listen episode. Topics Covered 00:00 – Introduction and Guest Welcome 00:53 – Reflecting on COVID-19's Psychological Impact 01:29 – Introducing the Iboga Patient Survey 01:46 – History and Goals of Ibogaine Research 02:41 – Challenges in Conducting Clinical Trials 03:14 – Importance of Real-World Safety Data 06:55 – Personal Interest in Ibogaine 08:56 – Veterans and Trauma: A Personal Connection 10:53 – Reintegration and Emotional Processing 15:29 – Survey Participation and Accessibility 18:25 – Building Partnerships and Overcoming Challenges 21:06 – Ensuring Safety and Transparency 31:49 – Community and Academic Collaboration 33:06 – Survey Design and Future Research Directions 36:50 – Momentum in Psychedelic Research 37:48 – State vs. Federal Regulation 39:23 – Challenges in Psychedelic Treatment 43:01 – Corporate Interests and Scientific Objectivity 47:20 – Ketamine and Collaborative Research 51:56 – Ibogaine Patient Survey 57:55 – Psychedelics and Pain Research 01:07:22 – Conclusion and Future Directions
In this engaging episode of the Psychedelics Today podcast, host Joe Moore sits down with Karina Bashir, an attorney working at the intersection of law, business ethics, and psychedelics. Karina, of counsel with Antithesis Law and an active member of the psychedelic community, shares her unique journey from human rights advocacy into the evolving field of psychedelic law. The conversation explores her presentation at Harvard on psychedelics and monotheistic religions, and her efforts to bridge the gap between Islamic communities and psychedelic-assisted healing. She discusses the legal frameworks she navigates to support clients in the psychedelic ecosystem, the spiritual depth of Sufism, and the expansive tradition of Islamic philosophy and mysticism. If you're intrigued by the intersections of religion, law, and psychedelic healing, this episode offers deep insights and hopeful perspectives.
In this deeply important episode of Psychedelics Today, Joe Moore is joined by Kristen Nash, MPH, and returning guest Erica Siegel, LCSW, for a nuanced conversation about risk reduction, harm prevention, and ethical education in the psychedelic space. Kristen shares the powerful and heartbreaking story of losing her 21-year-old son after a tragic psychedelic-related incident. Motivated by this loss and her background in public health, she founded the Coalition for Psychedelic Safety and Education and launched the Before You Trip campaign—an educational initiative piloting in Colorado aimed at helping Gen Z users assess their readiness and safety before engaging with psychedelics. Erica contributes her extensive experience from Nest Harm Reduction and Shine Collective, emphasizing the need for peer-based support, non-abstinence frameworks, and trauma-informed approaches. She highlights common pitfalls such as untrained facilitators, predatory behavior, and the pervasive issue of gaslighting in psychedelic communities. Together, they explore the gaps in current education efforts, the dangers of glorifying substances without context, and the moral injuries that can occur when people are harmed or dismissed by the very communities meant to support them. The conversation calls for broader public funding, lived-experience-informed leadership, and transparency around psychological and relational risks—not just physiological harm. The episode also touches on poly-substance use, the limitations of existing drug harm scales, and the importance of setting, support, and intention. With a shared commitment to saving lives and empowering users, Kristen and Erica offer actionable insights and heartfelt reflections on making this space safer for everyone. Listeners are encouraged to follow and support both Before You Trip and Shine Collective to help expand harm reduction education and survivor advocacy.
In this episode, Joe Moore speaks with award-winning science journalist Erica Rex about her personal experience participating in psychedelic research, her upcoming book Seeing What Is There: My Search for Sanity in the Psychedelic Era, and the complex story behind the recently published Religious Leader Psilocybin Study from Johns Hopkins and NYU. They examine: Erica's firsthand experience as a participant in the original 2012 study that helped launch Roland Griffiths' prominence in psychedelic science. The goals and outcomes of the Religious Leader Study, which sought to explore how psilocybin might impact religious leaders' effectiveness and connection to their communities. The methodological and ethical problems that plagued the study. The influence of perennialist frameworks and the limitations of measures like the Mystical Experience Questionnaire (MEQ). Broader concerns about the infiltration of religious ideology and lack of rigor in psychedelic science. A deep critique of the institutional systems that allowed flawed research processes to go unchecked — and how these patterns risk repeating the mistakes of the 1960s psychedelic wave. Joe and Erica also dive into how modern psychedelic science struggles to reconcile subjective experience, spirituality, and the reductionist standards of academic research. They discuss Matt Johnson's paper critiquing “psychedelic consciousness” framing and explore whether our current scientific tools are capable of capturing the depth of psychedelic experience. Erica's forthcoming book, slated for release in January 2026, blends memoir, neuroscience, and social critique. It offers a critical insider's view of the psychedelic renaissance—its promise, pitfalls, and the ways it mirrors broader systemic issues in science and culture.
In this expansive episode of Psychedelics Today, Joe Moore sits down with author and cultural theorist Daniel Pinchbeck to explore the evolving—and increasingly contested—role of psychedelics in society. From the hopeful spirit of transformation that animated earlier psychedelic movements to the sobering reality of biotech, branding, and political entanglement, Daniel offers a candid diagnosis of where we are—and where we might be headed. Reflecting on Psychedelic Science 2025, Daniel discusses the event's stark shift toward commercialization and industry influence. He contrasts this with his earlier work on Evolver, a movement that sought to integrate psychedelics with permaculture, alternative economics, and cultural awakening. Together, Joe and Daniel examine how the field's idealistic origins have been increasingly subjected to capitalist co-option. They also dive into deeper philosophical terrain—discussing monistic idealism, Rudolf Steiner, and the suppression of mystical and paranormal dimensions in the push to medicalize and sanitize psychedelics for mainstream acceptance. Daniel warns of the dangers of ignoring the shadow, including psychic fragmentation and what he calls "entity attachment" from ungrounded use. The conversation ranges from tech billionaires on ketamine to the geopolitical threat of authoritarianism, the weaponization of AI, and the quiet complicity of many in the psychedelic space who avoid political engagement. Daniel shares his current projects, including his Substack newsletter and a new seminar, Breaking the AI Barrier. This is a timely, unflinching exploration of psychedelics as both medicine and mirror—revealing the best and worst of our collective intentions. Can we reclaim the visionary potential of these tools from the grip of capital and control?
In this wide-ranging conversation, journalist Mattha Busby joins Joe Moore to reflect on the shifting tone of the psychedelic movement in the wake of Psychedelic Science 2025. Based in Vancouver, Mattha has written for The Guardian, VICE, Esquire, TIME, and Wired, bringing a uniquely embedded yet critical lens to the space. They discuss the post-conference mood and the sense that the industry is sobering up—less hype, more introspection. Mattha reflects on the growing division between underground practitioners, activists, and biotech startups, and the importance of vision, ethics, and scrutiny in the midst of this cultural moment. Other topics include: Ketamine overuse and dependence, especially in social and parenting contexts The future of psychedelic nightlife, harm reduction, and mocktail bars Gender and sexual fluidity as uncovered through psychedelics Questions of IP, underground wisdom, and psychedelic ownership Psychedelics as tools for peacebuilding, especially in conflict zones The shadow side of spiritual experiences and how to spot bad actors The value of pleasure, intimacy, and human connection in the psychedelic journey Joe and Mattha also reflect on the resurgence of psychedelic use in Texas, the legacy of the Stark Club, and how Christian libertarianism and military trauma might influence unexpected policy changes. This conversation is bold, honest, funny, and thoughtful—exactly the kind of cultural critique the movement needs right now. Find Mattha on Instagram at @matthamundo and on LinkedIn at Mattha Busby. His new pocketbook on drug policy is available now.
Dylan Beynon: At-Home Ketamine Therapy, Big Pharma Pushback, and the Future of Psychedelic Accessibility In this episode, Joe Moore welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S. Dylan shares the deeply personal story that led him to psychedelic medicine—including the tragic loss of his mother and sister to addiction and mental illness—and how these experiences continue to fuel his mission to make psychedelic therapy affordable and accessible for all. Mindbloom has now facilitated over 654,000 sessions across 38 states, offering both sublingual and subcutaneous (injectable) ketamine in a comprehensive treatment program that includes preparation, integration, music, journaling, and even generative AI art. The conversation dives into common criticisms of at-home ketamine, the benefits of guided treatment over IV infusions, and the disturbing influence of Big Pharma in media narratives—especially the growing PR push behind SPRAVATO. Dylan also breaks down what makes Mindbloom's outcomes stand out, why they recently added injectable ketamine, and how their safety data challenges popular misconceptions. Joe and Dylan also touch on the potential future of at-home MDMA therapy, regulatory hurdles, and what it will take to scale these powerful treatments to millions of people in need. If you're in the psychedelic field, considering ketamine therapy, or curious about the ethics and economics of psychedelic medicine, this episode offers a powerful look behind the curtain. Resources: Mindbloom.com Vital Psychedelic Training
In this episode, we sit down with Victoria Litman, M.Div., J.D., LL.M., to discuss why the future of psychedelic access in the United States is being shaped not by federal agencies, but by the bold actions of individual states. As a legal scholar and writer focusing on drug policy, Victoria breaks down the significance of the FDA's 2024 rejection of psychedelic-assisted therapy, and why that decision might be less of a setback than it seems. We explore how state-level initiatives like Oregon's Psilocybin Services Act and Colorado's Natural Medicine Health Act are setting the stage for a new model of access—one rooted in harm reduction, personal liberty, and existing regulatory infrastructure. Victoria discusses the importance of the Tenth Amendment and the Anti-Commandeering Doctrine, which allow states to move forward regardless of federal inaction. Rather than waiting for slow-moving federal institutions, Victoria argues that states can build safe, scalable systems now—especially by leveraging cannabis infrastructure for psychedelic regulation. She also touches on the ethical and cultural implications of this transition, including protections for spiritual and religious use. If you're wondering what psychedelic policy will look like in the years ahead, this episode offers an insightful and hopeful roadmap. Link to CATO article
Joe Moore and Anne Philippi are hosts of the PS25 Morning Show! This one features Dee Dee Goldpaugh, LCSW and Tommaso Barba, PhDC! We talk about all things Sex and Psychedelics!
n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world's leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale. Trevor shares his early work supporting marginalized populations in Vancouver's Downtown Eastside, which led to the founding of Liberty Root, one of Canada's first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021. They discuss: The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk. Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California. Ambio's groundbreaking neuroregenerative program for Parkinson's, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker. How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford's 2024 study on Special Forces veterans. Why ibogaine isn't just a molecule – it opens a long-lasting “critical period” of neuroplasticity that must be supported with preparation, integration, and holistic care. The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains. Their cautionary perspective on Texas' $50M push toward ibogaine clinical trials – and why the traditional “one drug, one indication” model misses the complexity and promise of psychedelic healing. They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. “Start with the end in mind,” Trevor urges – Ambio isn't just part of the movement; it's the blueprint for how ibogaine could be delivered worldwide. Links: Ambio Website: https://ambio.life/ Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (Frontiers in Immunology, Feb 2025) Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature Medicine, Jan 2024) Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion (Frontiers in Pain Research, Aug 2023) Novel treatment of opioid use disorder using ibogaine and iboga in two adults (Journal of Psychedelic Studies, Jan 2020) Clinical Guidelines for Ibogaine-Assisted Detoxification Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions Bios: Jonathan Dickinson is the Chief Executive Officer and Co-Founder of Ambio Life Sciences. One of the world's leading experts on ibogaine, Jonathan brings over 15 years of experience in clinical care, traditional practice, and psychedelic research to his leadership at Ambio. A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, he authored the field's foundational safety guidelines and has published widely on ibogaine's therapeutic, cultural, and ecological significance. He holds the only active export license for Tabernanthe iboga root, led the first Nagoya-compliant export from Gabon, and was initiated into the Dissoumba/Fang tradition of Bwiti in 2014 and the Missoko tradition in 2022. He has co-authored peer-reviewed research on ibogaine's potential for trauma, TBI, pain, MS, and Parkinson's. At Ambio, he leads strategy, research, and innovation – advancing a globally scalable model of care that bridges tradition, science, and integrity. Trevor Millar is the Chief Operating Officer and Co-Founder of Ambio Life Sciences. A social entrepreneur and pioneer in ibogaine advocacy and treatment, Trevor brings over a decade of experience supporting individuals through addiction recovery, trauma healing, and post-treatment integration. His background includes co-founding the Canadian Psychedelic Association and serving as Chair of the Board for MAPS Canada. He has co-authored peer-reviewed research on ibogaine's applications for trauma, TBI, and opioid use disorder, and has been featured in award-winning documentaries including DOSED and In Waves and War. Grounded in personal experience and guided by a philosophical approach to healing, Trevor is helping shape a new model for ethical, integrative psychedelic care on a global scale. At Ambio, Trevor leads operations, strategic partnerships, and client experience – bridging clinical care with systems design, education, and public advocacy.
In this episode of Psychedelics Today, hosts sit down with Jeff Breau from Harvard Divinity School's Center for the Study of World Religions. Key themes include the intersection of psychedelics and religion, harm reduction practices, and the burgeoning psychedelic church movement. Jeff brings insights from his ethnographic research on psychedelic churches and discusses the importance of interdisciplinary collaboration for advancing understanding in this field. He also delves into the role of music in psychedelic therapy, critiques of the Mystical Experience Questionnaire (MEQ), and the potential for psychedelic chaplaincy. Tune in for an enlightening conversation on the evolving landscape of psychedelics in society and spirituality. 00:00 Introduction and Welcome 00:18 Music in Psychedelic Therapy 02:13 Cultural Context of Music in Therapy 06:08 Personal Journey into Psychedelics and Religion 08:40 Living at an Ashram and Spiritual Practices 15:52 Mystical Experience Questionnaire (MEQ) 33:01 Psychedelic Churches and Legal Challenges 46:11 The Intersection of Law and Religion 46:34 Emergence of Psychedelic Churches 48:41 The Democratization of Mystical Experiences 49:49 Technologies of Revelation 51:10 Novel Rituals and Spiritual Practices 53:49 Humor and Irreverence in Religion 56:44 Reevaluating the Term 'Cult' 01:10:11 Psychedelic Chaplaincy and Spiritual Care 01:18:44 Burning Man as a Model for Religiosity 01:22:43 The Rise of Iboga in American Christianity 01:25:56 Conclusion and Future Directions Links https://cswr.hds.harvard.edu/people/jeffrey-breau
In this episode, Joe Moore sits down with Paul Gillis-Smith from The Center for the Study of World Religions to discuss a range of fascinating topics. They begin by discussing the Harvard Divinity School and the CSWR's mission and history. The conversation delves into the work and legacy of Lisa Bieberman, a pivotal figure in the 1960s psychedelic harm reduction movement. It explores her contributions to the field through her Psychedelic Information Center. They also touch on the Quaker traditions and their intersection with LSD use, showing how spirituality and psychedelics can coalesce. Paul also talks about upcoming psychedelic and chaplaincy workshops, emphasizing the importance of spiritual care in psychedelic experiences. This episode is rich with historical insights and contemporary applications, making it a must-listen for anyone interested in psychedelics and spirituality. Paul Gillis-Smith @ CSWR Center for the Study of World Religions Psychometric brahman, psychedelic science: Walter Stace, transnational Vedanta, and the Mystical Experience Questionnaire 00:00 Introduction and Initial Setup 00:34 Meeting at Penn's Psychedelic Conference 01:14 Postdoctoral Presentations and Indigenous Plant Medicine 03:27 Understanding CSWR and Its Evolution 07:21 Harvard's Study of Psychedelics in Society and Culture 09:11 Personal Academic Journey and Interest in Psychedelics 11:58 Role at CSWR and Ongoing Projects 18:59 Lisa Bieberman: A Pioneer in Psychedelic Education 40:53 Quaker Theology of LSD 41:58 Meeting Structure and Frequency 42:46 Profound Simple Truths 45:41 Transition to Quakerism 48:45 The New Jerusalem Prophecy 53:02 Quakerism and Its Influence 01:11:25 Clinical Chaplaincy and Psychedelics 01:18:39 Conclusion and Future Projects
In this episode of Psychedelics Today, Joe Moore speaks with Dr. Simon Ruffell, a London-based psychiatrist, researcher, and curandero-in-training in the López Mahua lineage of the Shipibo tradition. Dr. Ruffell shares how his early fascination with psychiatry eventually led to a deep disillusionment with the limitations of conventional treatments—and a surprising pivot toward the Amazon. Now working at the intersection of Indigenous healing and clinical research, Ruffell describes his journey from medical school to shamanic apprenticeship. He offers insight into the Shipibo understanding of illness across three planes—spiritual, psychological, and physical—and how these ideas challenge Western frameworks. The conversation explores critical questions about the psychedelic renaissance: Are current clinical models missing the energetic and spiritual dimensions of healing? What are the risks of poorly held psychedelic sessions, and how can Indigenous knowledge guide safer practices? Dr. Ruffell advocates for deep training, cross-cultural respect, and collaborative models—such as pairing Indigenous healers with psychiatrists in clinical settings. He also discusses his work with Onaya Science and Onaya.io, organizations that partner with Indigenous communities to study the effects of ayahuasca, particularly in treating PTSD among military veterans. Early findings from their five-year study show that 84% of participants no longer meet PTSD criteria six months after retreat—a promising signal for integrative approaches. This episode offers a rare look at how science and spirituality can coexist. Whether you're a clinician, researcher, or someone seeking deeper healing, Dr. Ruffell's story invites us to question our assumptions and expand our understanding of what true medicine can be.
Aspen Psychedelic Symposium 2024 – Hosted by Kevin Franciotti This powerful panel explores the healing potential and complex responsibilities that come with working with Ibogaine, a potent plant-based psychedelic. Moderator Kevin Franciotti guides a heartfelt and informative conversation with Talia Eisenberg, Tom Feegel, and Dr. Lola "Dr. O" Hoba, highlighting personal transformation, medical protocols, and the importance of honoring traditional knowledge. Personal Journeys with Ibogaine Talia Eisenberg shares her recovery from opioid addiction and the founding of BEOND Ibogaine, a medical treatment center in Cancun, Mexico. Her story illustrates the plant's unique power to interrupt addiction and awaken purpose. Tom Feegel, co-founder and CEO of BEOND, shares how his own trauma and long-term sobriety inspired a vision for a safe, respectful, and medically supervised environment for deep healing. Clinical and Cultural Wisdom Dr. Lola Hoba offers insights as a pharmacist and Yoruba herbalist, bridging traditional plant medicine knowledge with modern pharmacology. She describes how iboga works on multiple brain receptors and why it holds so much promise for treating addiction, depression, and trauma. She also cautions about its cardiac risks and calls for respectful, trained facilitation. Safety, Access, and Sustainability Panelists discuss the rigorous safety protocols at BEOND, including ICU-level care, psychiatric screening, and pre-treatment evaluations. They also explore broader questions: How can this medicine be offered responsibly? What does reciprocity mean in practice? BEOND supports Blessings of the Forest, a nonprofit in Gabon that works to stop poaching and protect Indigenous access to the sacred root. A Call for Balance and Respect This conversation highlights the importance of blending science, spirit, and social justice. From trauma healing to sustainable sourcing, each panelist emphasizes the need for compassion, caution, and connection. As laws change and access grows, the panel urges all involved to move forward with care—for the medicine, the people it serves, and the cultures that have stewarded it for generations.
A panel discussion with Jim Harris, Rachel Zoeller, DPT, David W. McMillan, Ph.D., and Manesh Girn, Ph.D. Recorded live at the Aspen Psychedelic Symposium In this riveting and deeply personal conversation, moderator Jim Harris is joined by three pioneers at the intersection of neuroscience, psychedelics, and disability: Dr. Rachel Zoeller (Doctor of Physical Therapy and spinal cord injury survivor), Dr. David McMillan (Assistant Professor of Neurological Surgery at the University of Miami), and Dr. Manesh Girn (neuroscientist and postdoctoral researcher with Robin Carhart-Harris at UCSF). Together, they explore how psychedelics may do far more than treat depression or catalyze mystical experiences—they may also support healing and regeneration in the nervous system. The discussion opens with an acknowledgment that our cultural understanding of psychedelics has mostly focused on their psychological and spiritual effects. But as these experts reveal, the somatic potential of psychedelics is vast and understudied. They delve into promising areas like central and peripheral neuroplasticity, the anti-inflammatory effects of psychedelics, and how these mechanisms might play a role in healing from spinal cord injuries or paralysis. Dr. Girn breaks down the science behind psilocybin's interaction with 5-HT2A serotonin receptors, not only in the brain but also in the spinal cord. These receptors, when activated, may increase neuronal excitability and even help restore lost signaling in damaged motor pathways. He suggests that psychedelics could reopen “critical periods” for neuroplasticity—windows of opportunity for the nervous system to rewire and heal. Rachel Zoeller shares her powerful lived experience as both a physical therapist and a spinal cord injury patient. Her story brings the science to life, particularly her observation that psychedelic experiences help her reconnect to parts of her body affected by paralysis. Psychedelics, she suggests, have allowed her to rebuild mind-body communication and foster compassion toward her own physical limitations. She also underscores the need for patients to cultivate body awareness, meditation, and breathwork as essential tools for safe and effective psychedelic use. Dr. McMillan, who leads outreach at the Miami Project to Cure Paralysis, provides a clinical and safety-oriented perspective. While optimistic about the potential, he urges caution—especially with individuals who have high-level spinal cord injuries and are vulnerable to serious complications like autonomic dysreflexia. He stresses that before we can bring these treatments into clinical settings, we must carefully assess physiological risk, develop precise pharmacological protocols, and prioritize patient safety. The panel also addresses cultural and spiritual interpretations of spasticity. Drawing on both shamanic and somatic perspectives, they propose that these involuntary muscle contractions could be reinterpreted not as dysfunction, but as potential portals for healing, integration, or neurological feedback. The idea that such spasms might help the brain remap muscle groups is discussed as a provocative and hopeful reframe. The conversation wraps with a call to action: to bring together indigenous wisdom, embodied knowledge, rigorous science, and community storytelling in order to chart a new frontier in psychedelic medicine—one that does not leave the disabled community behind. As McMillan puts it, "There's a lesson to psychedelia from paralysis.” It's a reminder that neuropharmacology must consider not just molecules and mechanisms, but people and possibilities. Whether you're a clinician, researcher, patient, or curious explorer, this panel is a moving and illuminating look at how psychedelics could transform not only minds—but bodies. Thanks to Aspen Public Radio, Aspen Psychedelic Resource Center, Healing Advocacy Fund and Aspen Psychedelic Symposium for allowing us to share this podcast. A full agenda from the symposium can be found here.
In this special panel, Joe Moore of Psychedelics Today is joined by Sandor Iron Rope, Lakota spiritual leader and peyote practitioner, and Zach Leary, writer and advocate for psychedelic culture. Together, they explore the critical importance of respecting the cultural, spiritual, and ecological roots of plant medicines. Sandor shares powerful reflections on the Lakota worldview, the trauma of colonization, and the deep spiritual kinship indigenous peoples hold with medicinal plants. Zach reflects on the American counterculture's relationship with psychedelics, highlighting the need to preserve mysticism and community over commercialization. The panel dives into challenges around synthetic versus natural medicines, the risks of spiritual harm when practices are rushed or disconnected from tradition, and the urgent need for indigenous voices at the table as psychedelic policy evolves. Throughout, a theme emerges: slow down, honor kinship, and build right relationship with nature, culture, and spirit. This conversation offers a rare and necessary bridge between indigenous wisdom and the psychedelic resurgence, calling for respect, collaboration, and a return to deep roots to guide future generations. Learn more at ipci.life and psychedelicstoday.com.
This podcast comes from the Aspen Psychedelic Symposium from last summer. It features Diane Goldstein who is the executive director of Law Enforcement Action Partnership, Sarko Gergerian a police officer from Winthrop, Mass and Rick Doblin from MAPS. This panel was introduced by Zach Leary and was a highlight of our trip to Aspen's conference last year. We discuss new ways in which police should or could consider psychedelics and drugs more generally. Thanks to Aspen Public Radio and Aspen Psychedelic Symposium for allowing us to share this podcast.
In this episode Kyle Buller and Joe Moore speak to Zach Leary about his new book "Your Extraordinary Mind: Psychedelics in the 21st Century and How to Use Them". Kyle and Joe join Zach in person for this recording. Zach has lots of hard earned wisdom and gracefully shares it with us and with his readers. We discuss MAPS PS25, Psychedelic Churches, psychedelic overuse and much more. Join us to learn more.
In this episode, Joe Moore welcomes LP Giobbi, an internationally famous DJ, electronic music producer, and jazz pianist. LP shares the story behind Dead House, her project blending Grateful Dead samples with house music. What started as a tribute to her parents during pandemic live streams has become a celebrated musical movement. Joe and LP explore the deeper connection between music and psychedelics. They talk about Bicycle Day, the story of Albert Hofmann's famous LSD bike ride, and how psychedelics can support creativity and personal growth. LP opens up about her own experiences with psychedelics, touring burnout, and how she's learning to reconnect with her body through music and intention. The conversation also highlights LP's work with Fem House, an educational platform that empowers women and gender-expansive individuals in music production. She explains how representation, access, and support are key to shifting the music industry. This is a warm, inspiring, candid episode about breaking barriers, finding your voice, and leading purposefully. If you're in Denver, catch Dead House live at Meow Wolf on Bicycle Day!
In this episode, Kyle Buller speaks with Kayse Geheret, founder of Microdosing for Healing and instructor for Psychedelics Today's Vital program. They explore what it means to be a modern guide in the world of psychedelics. Kayse shares how microdosing has become a key entry point for many and highlights the importance of training, community, and personal growth. They discuss how not all psychedelic work involves facilitation. Some guides support through integration, education, or community organizing. The conversation covers what makes a great guide—qualities like groundedness, empathy, curiosity, and the ability to hold space. They also talk about the growing need for psychedelic-literate professionals in all fields, not just therapy. Kayse and Kyle reflect on the importance of finding the right training—whether for coaching, integration, or peer support. With more people entering the space, education and connection are more important than ever. Whether you're curious about microdosing, thinking of becoming a guide, or simply want to better support your community, this episode offers valuable insight.
Joe Moore sits down with UK-based artist Harry Pack, whose vibrant, surreal, and often psychedelic art has captured the attention of dreamers, psychonauts, and seekers worldwide. Known for channeling the aesthetic of altered states rather than simply replicating them, Harry discusses his journey from childhood doodles to being a full-time artist working digitally in Procreate. He shares stories of deep inspiration from figures like Ott—whose album Hiraeth he recently illustrated—and how art has helped him integrate mystical experiences, recovery, and even potential alien contact. The conversation explores the therapeutic potential of art, the role of storytelling in visionary creativity, and the emergence of recurring themes in Harry's work—most notably, the enigmatic “Purple UFO.” We also get into the importance of community, nature, and play in feeding the creative spirit, and Harry's aspirations to build spaces for collective art-making and integration. Follow Harry on Instagram @harrypackart and @thepurpleufo, and explore his work at harrypackart.com.
In this episode of Psychedelics Today, Joe Moore sits down with South African ethnobotanist and healer Jean-François Sobiecki to explore the rich and largely underrecognized world of African psychoactive plants. With over two decades of fieldwork and research, Jean-François sheds light on the traditional use of these plants in healing, divination, and spiritual practices across Southern Africa. Topics covered include: Jean-François's early inspirations and the ancestral roots of his herbal knowledge His discovery and documentation of 306 African psychoactive plant species The ritual use of Ubuwalu (dream-enhancing emetic infusions) and their role in personal transformation How vomiting, dietary restrictions, and sensory isolation are used as part of initiation processes Cross-cultural parallels between Southern African and Amazonian plant healing traditions The underexplored use of psychoactive plants to treat mental health conditions like schizophrenia and hysteria Ethical fieldwork, indigenous knowledge protection, and the dangers of overharvesting sacred plants Visions for healing and conservation gardens in Africa and the role these plants could play in global mental health Jean-François shares moving stories of his 15-year mentorship with a Northern Sotho diviner and healer, Letti Ponnya, and how she introduced him to African “plant teacher” medicines. His message is clear: Africa has a deep, sophisticated, and scientifically underappreciated tradition of psychoactive plant use that deserves recognition, respect, and further study.
In this inspiring and far-reaching conversation, Joe Moore is joined by Vince Kadlubek, the founder and Chief Visionary Officer of Meow Wolf, the groundbreaking arts and entertainment company known for its massive, immersive art experiences. Together, they dive deep into Meow Wolf's humble DIY origins, its evolution into a multi-city creative juggernaut, and how it intertwines with psychedelic culture and expanded states of consciousness. Vince shares the story of Meow Wolf's formation in Santa Fe, the evolution from a group of passionate friends into a thousand-person company, and the power of belief, creativity, and visionary leadership. He reflects on raising funding from George R. R. Martin and major investors, navigating massive growth, and the challenge of keeping the creative spark alive in the face of institutionalization. They also discuss the upcoming Bicycle Day Portal Takeover at Meow Wolf Denver on April 19, which will feature performances, talks, and immersive experiences throughout the exhibition—with appearances from Reggie Watts, Duncan Trussell, Zach Leary, and more. From the imaginative to the esoteric, Vince and Joe explore the intersection of psychedelics and art, the nature of reality and the imaginal realm, and how to build beauty and wonder into the world around us.
In this episode, Joe interviews Fayzan Rab, an MD candidate (when we recorded) at Emory University with a background in tech at Google and a focus on the intersection of psychedelics, spirituality, and public health. Fayzan shares Emory's unique approach to psychedelic studies, emphasizing spiritual health and the lived religious and existential aspects of psychedelic experiences—what he and his team call “CERT.” The conversation explores Fayzan's collaboration with health economist Elliot Marseille on economic modeling for psilocybin therapy, including their estimate that over 5 million Americans could be medically eligible. He shares insights into the policy challenges around payer systems and the importance of preparing implementation strategies before FDA approval. Fayzan also discusses his groundbreaking research on Muslim perspectives on psychedelics—revealing surprising openness, complex spiritual tensions, and a strong interest in integrating these substances into healing and faith-based frameworks. He highlights the need for inclusive infrastructure and upcoming work with clergy to deepen the conversation. Finally, they explore non-clinical psychedelic use among healthcare workers and entrepreneurs, discussing how psychedelics are being used to address burnout, identity, and life purpose. This is a powerful episode about interdisciplinary collaboration, cultural sensitivity, and the potential for psychedelics to transform not just individuals—but systems. Links Science on Spiritual Health Symposium 2025 Center for Psychedelics and Spirituality - Emory University
In this episode of Psychedelics Today, Kyle Buller is joined by Dr. Hannah McLane, founder of the SoundMind Center and SoundMind Institute. They dive deep into the evolving psychedelic landscape—touching on policy developments in New Jersey, Massachusetts, Pennsylvania, and beyond. Dr. McLane shares her experience testifying in support of psilocybin legislation and discusses the medical frameworks being explored, particularly in contrast to Oregon and Colorado's models. The conversation also explores the essential qualities of effective psychedelic facilitators, emphasizing the importance of self-awareness, lifelong learning, and doing personal inner work. Dr. McLane offers insights into the challenges of entrepreneurship in the psychedelic space, balancing mission-driven work with sustainability, and how neurodiversity and trauma have shaped her approach. Toward the end, the conversation takes a playful and heartfelt turn, reflecting on parenting, the power of curiosity, and the need for more community-centered, human-first spaces for integration and healing. This is a rich, honest, and inspiring dialogue that bridges the personal and political, the clinical and ceremonial, and the visionary future of psychedelics.
In this powerful episode of Psychedelics Today, we sit down with the team behind Natural Medicine Alaska to discuss their groundbreaking efforts to bring psychedelic reform to the state. With some of the highest rates of depression, suicide, and substance use disorders in the nation, Alaska stands at a pivotal moment in the movement for mental health transformation. Joe Moore speaks with Gina, President of Natural Medicine Alaska; David Aloff, an Alaska Native advocate; and Noria Clark, Veterans Coordinator to explore the origins of their movement, the importance of traditional healing protections, and their 2026 ballot initiative to decriminalize plant medicines and establish a regulated therapeutic model. The discussion dives into: The personal journeys that led each guest to this work How Alaska's libertarian spirit aligns with psychedelic reform The push to make Alaska the first state to include Ibogaine clinics in legislation The urgent need for veteran and first responder access to psychedelic therapy Fundraising and grassroots efforts to get the initiative on the ballot The role of Alaska's natural landscape in healing and psychedelic integration With national psychedelic policy at a crossroads, Alaska has the opportunity to become the North Star of this movement. Listen in to learn how you can support this critical campaign! Support Natural Medicine Alaska:
Podcast Show Notes: Psychedelics, Harm Reduction & Ethical Care with Erica Siegal In this episode of Psychedelics Today, Joe Moore sits down with Erica Siegal, founder of Nest Harm Reduction and Shine Collective, for a deep conversation on psychedelic harm reduction, ethical facilitation, and the evolving psychedelic landscape. Erica shares her journey from the Grateful Dead lot scene to festival harm reduction, social work, and leading initiatives to support survivors of psychedelic-related harm. The conversation covers: Erica's background in hospitality, social work, and psychedelic harm reduction The mission of Nest Harm Reduction in offering psychedelic therapy, integration, and community education The work of Shine Collective, a nonprofit supporting survivors of psychedelic harm and abuse The challenges of ethical facilitation, power dynamics, and the importance of clear boundaries How the psychedelic community can better address harm, accountability, and survivor support The intersection of Jewish spiritual traditions and psychedelics through Shefa This episode is a must-listen for those passionate about harm reduction, ethical psychedelic practice, and building a safer, more accountable psychedelic culture.
Army Ranger to consultant to leading one of the most respected psychedelic retreat organizations, detailing how meditation and psychedelic therapy helped him heal from trauma. The conversation covers: Neal's military background and his path to psychedelics The mission and structure of Beckley Retreats, an offshoot of the Beckley Foundation How their retreats integrate meditation, preparation, and integration for long-lasting benefits The legal landscape of psilocybin in Jamaica and the Netherlands Challenges and lessons from running a psychedelic retreat business The future of psychedelics, from global access to potential federal policy shifts Whether you're curious about immersive psychedelic retreats, the intersection of mental health and psychedelics, or the evolving legal landscape, this episode is packed with insight. Learn more about Beckley Retreats here. Hear more from Neil on Psychedelics Today here.
In this episode, Joe Moore of Psychedelics Today sits down with Paul Austin, founder of The Third Wave, to dive deep into the evolution of microdosing and its growing role in psychedelic culture. Paul shares how his journey with microdosing LSD led him to launch The Third Wave in 2015 to make psychedelics more accessible through education. The conversation explores the latest research on microdosing, including clinical trials demonstrating its potential benefits for depression, mental clarity, and creativity. Paul and Joe discuss the nuances of different microdosing protocols, the role of psychedelics in performance optimization, and the impact of these substances on neuroplasticity. They also tackle key challenges, such as the lack of robust clinical research due to regulatory hurdles and the perceived risks associated with overuse. Beyond microdosing, they touch on the broader psychedelic landscape—regulatory shifts, emerging coaching models, and the future of psychedelic-assisted transformation. The discussion even ventures into intriguing intersections between psychedelics, AI, and the possibility of extraterrestrial intelligence. Tune in for a thought-provoking conversation on where microdosing fits into the larger psychedelic resurgence.
In this episode of Psychedelics Today, Joe Moore sits down with Louis Dorian, the visionary behind Psychedelist, a groundbreaking global platform designed to support the emerging psychedelic movement. Described as a “cyber city” for all things psychedelic, Psychedelist connects individuals with treatment providers, educators, facilitators, legal experts, and even vetted product vendors in an effort to enhance accessibility and safety in this evolving space. Louis shares his journey into psychedelics, from early rave days to a transformative encounter with high-dose LSD and psilocybin that shaped his worldview. He opens up about the struggles of navigating trauma, loss, and the shortcomings of Western psychiatric care, leading him to develop his own trauma-processing techniques blending meditation, breathwork, and psychedelics. The conversation also dives deep into the broader implications of drug prohibition, harm reduction, and the role of skill-building in responsible psychedelic use. Whether you're a seeker, a skeptic, or a professional in the field, this episode offers a compelling exploration of the psychedelic landscape and the power of intentional community building. Resources: Visit Psychedelist Follow Louis Dorian on Instagram: @psychedelist More from Psychedelics Today: Website Tune in for an eye-opening discussion on the future of psychedelics, regulation, and self-exploration!
In this episode of Psychedelics Today, Joe Moore is joined by Neeka Levy and Zach Skiles of Heal Ukraine Trauma, a nonprofit bringing psychedelic-assisted therapy to veterans and civilians affected by war. They discuss the organization's origins, the impact of intergenerational trauma in Ukraine, and the evolving role of psychedelic treatments in a war-torn nation. Nika, a first-generation Ukrainian-American and neuroscience-trained psychiatric nurse practitioner, and Zach, a Marine veteran turned psychologist, share their journey into this work, highlighting the importance of group ketamine therapy as a scalable, culturally aligned solution. They explore Ukraine's complex regulatory landscape, the need for rigorous research, and the challenges of working in a war zone. They also touch on the role of psychedelics in processing moral injury, the importance of including family members in healing, and how Ukraine's collectivist culture influences therapeutic approaches. With insights on historical trauma, ethical considerations, and the potential future of MDMA and psilocybin therapy in Ukraine, this conversation sheds light on a vital, evolving effort.
In this episode, Joe interviews Josh Lipson, a Ph.D. candidate in clinical psychology at Columbia University, whose research explores the relationship between psychedelics, mystical experiences, and mental health. He discusses the complexities of studying psychedelics in real-world settings, the role of metaphysical perspectives in research, and why different individuals respond to psychedelics in such varied ways. Lipson shares his personal journey into psychedelic research, the challenges of interdepartmental collaboration, and the evolving landscape of modern psychedelic science. He also talks about: The importance of integration after psychedelic experience Why mystical experiences may not be the only path to healin The balance between stability and the chaos psychedelics can introduc The need for diverse perspectives and ways of knowing in psychedelic researc How psychedelics have shaped global consciousness and cultural perspectives and more! For links, head to the show notes page.
In this episode, Joe interviews Nico and Susan Simon: Co-founders of JourneyŌM, a concierge service looking to address the question many people are asking: How do you find the right facilitator? Through a dedicated vetting process, JourneyŌM is adding a layer of risk reduction and accountability to this strange new world, by traveling the country and amassing a network of trusted facilitators who work with all types of medicines and modalities. By getting to know guides and seekers personally, they're able to offer possible matches – and they usually agree on who would work best with each other. They talk about: Their process for building their network and finding the right facilitator for someone Their concept of going “beyond the bio” and getting to the heart of what drove someone toward becoming a guide Susan's struggle with supporting Nico through his psychedelic healing, and the need for support options for spouses not sharing in the experience The importance of community and the amazing work Nico has seen in men's groups The healing powers of movement and living as your authentic self and more! If you're interested in JourneyŌM's matchmaking, head to their site and take their assessment to begin the process. For links, head to the show notes page.
In this episode, Joe interviews renowned chemist, filmmaker, and journalist, Hamilton Morris. After originally backing down from its first attempt in 2022, the DEA is once again looking to apply schedule I status to two lesser-known compounds: DOI (2,5-dimethoxy-4-iodoamphetamine) and DOC (2,5-dimethoxy-4-chloroamphetamine). For decades, DOI and DOC have been incredible tools for researchers studying serotonin receptors, showing promise for chronic pain, anxiety, depression, and more. Originally recorded as a livestream in November, we felt this discussion deserved more attention, as Morris was present during the hearing and saw first-hand the damage that can come from the combination of immense overreach and outdated beliefs. He talks about: The bureaucratic mess behind so much of what the DEA doe The safety profile and research capacity of DOI and DOC and complete lack of data showing recreational us The DEA's claim that advocates weren't expert The fight to protect the Sonoran Desert toad and more! While we wait for the conclusion of the hearing, head to Hamilton's Patreon to hear his daily breakdowns. For links, head to the show notes page.
In this episode, Joe interviews Jeremy Falk: certified instructor and training program developer for Kama Flight; and Dr. David Rabin, MD, Ph.D.: board-certified psychiatrist and neuroscientist, co-founder & chief Medical Officer at Apollo Neuroscience, and advisor to Kama Flight. Kama Flight is a wellness modality for partners, inspired by the movements of Watsu therapy, Thai massage, 5Rhythms, tango, improv dance, and Acroyoga. At the heart of it is the dynamic between the two people engaged in the dance (the ‘base' and the ‘voyager'), which touches on collaboration, leadership, receptivity, strength, surrender, and most importantly, trust. The communication and instant feedback shared between the partners mixed with the healing energy of the somatic movements results in moving stuck energy out of their bodies while also making them more comfortable with touch, agency, and consent – which could be extremely beneficial toward preparing for a psychedelic experience. They talk about: The four principles behind Kama Flight: permission, presence, polarity, and play The humility and humor in people trying (and failing) some of the movements, and how that is healing in itself The huge benefit in people switching between the roles of base and voyager What kind of growth they've seen in clients over extended periods of time The importance of making time for pleasure in our lives and more! For links, head to the show notes page.
In this episode, Joe interviews Ariel Clark: Anishinaabe attorney and co-founder of the Psychedelic Bar Association, a national association of lawyers involved in the highly-regulated ecosystem of psychedelic law. She talks about ethics: How do the different societal norms of each lineage we carry interact with each other? What is the cultural framing that informs those ways of knowing, and do we align with it? Is there a code of ethics we can all agree on? As the rush to legalize psychedelics increases, Clark finds herself at a crossroads of wondering if our actions are really of service to the greater good: Can the overculture legalize psychedelics effectively, while doing less harm to Indigenous culture and the medicines themselves? She discusses: The challenges of working in psychedelic law with all of the other factors at play: How do you ethically support a client? The idea that these medicines can have agency – even the synthetic ones Shifting from a Western mind state of “what are my rights?” to an Indigenous frame of: “What are my responsibilities?” Her story of healing from debilitating back pain with psychedelics and spiritual alignment The need for public education to be at the center of future legislation attempts and more! For links, head to the show notes page.